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Letter to the EditorMechanism of phosphatidylserine inhibition
of IgE/FcεRI-dependent anaphylactic human
basophil degranulation via CD300a
To the Editor:
The process that leads to histamine release from human
basophils constitutes a continuum that starts with piecemeal
degranulation and eventually converts to anaphylactic degranu-
lation (AND).1,2 These degranulation events are accompanied by
mobilization of distinct cellular compartments and expression of
surface molecules that are not or barely expressed on resting
basophils. Two different histamine-containing compartments,
which show distinct early signaling requirements and kinetics,
have been described, namely, the CD203c compartment and the
CD63 compartment.2,3 The appearance of CD63 is invariably
associated with AND.2Mechanisms that regulate basophil activa-
tion likely relate to activation conditions (IgE/FcεRI-dependent
and -independent), mode of degranulation (piecemeal degranula-
tion vs AND), and changes in functional properties of inhibitory
receptors.4 The inhibitory receptor CD300a (IRp60) is constitu-
tively expressed on human basophils and rapidly upregulated in
response to IgE/FcεRI cross-linking; its engagement selectively
suppresses AND without a significant effect on CD203c.5
Moreover, recently CD300a has been shown to be a receptor
for phosphatidylserine (PS) and phosphatidylethanolamine
expressed on the membrane of apoptotic cells.6
This study aimed at investigating the effect of PS recognition
by CD300a on IgE/FcεRI-dependent basophilic activation. Three
experimental models addressed (1) the effect of apoptotic K562
cells on IgE/FcεRI-mediated activation of basophils in whole
blood, (2) the putative role of PS, and finally (3) the effect of the
PS-binding molecule Annexin Vand CD300a-blocking antibody
on inhibitory signals delivered by apoptotic PBMCs on separated
basophils, excluding interference of other cells or humoral
factors.
For detailed information on experimental design, see the
Methods section in the Online Repository at www.jacionline.org.
Aliquots of whole blood from 5 patients and 5 controls were
preincubated with serial dilutions of viable or apoptotic K562
cells (from 20 3 107/mL to 20 3 102/mL; 378C, 30 minutes)
before stimulation with buffer (negative control) or with anti-
IgE (positive control) and, in patients, rBet v 1, the recombinant
major allergen from birch (Betula verrucosa) pollen (for detailed
information, see the Methods section). This resulted in a signifi-
cant dose-dependent inhibition of CD63 upregulation (Fig 1, A)
that was more pronounced in healthy subjects than in allergic pa-
tients (Fig 1, B; P < .05). Similar results were obtained with pa-
tients’ basophils stimulated with rBet v 1 (Fig 1, C). There was
no significant effect of viable or apoptotic K562 on the sponta-
neous expression of CD63 and CD203c on basophils (data not
shown).
Fluorescein-stained liposomes, noncoated or coated with PS or
phosphorylcholine, were added to magnetic bead–isolated
basophils7 of 2 healthy donors (48C, 20minutes) and immediately
assessed by flow cytometry (for detailed information about
liposomes preparation, see the Methods section). Next, the func-
tional effect of noncoated and PS- and phosphorylcholine-coated
liposomes was assessed by preincubating different concentrationsof nonstained liposomes with isolated basophils7 at 378C for 30
minutes before anti-IgE stimulation. These experiments revealed
that only PS-coated liposomes bind basophilic membranes (Fig 1,
D) and inhibit IgE/FcεRI-mediated activation of the cells in a
dose-dependent manner, starting with a ratio liposomes/basophil
20/1. As with apoptotic K562 cells, this effect was more pro-
nounced on the CD63 compartment (Fig 1, E; see Fig E1 in this
article’s Online Repository at www.jacionline.org).
To study the effect of the PS-binding molecule Annexin Vand
CD300a-blocking antibody (clone TX49), apoptotic autologous
PBMCs (ratio PBMCs/basophil 20/1) were used (n5 3). To bind
PS on the membrane of apoptotic PBMCs (aPBMCs), cells were
incubated with different concentrations of recombinant human
Annexin V at 378C for 30 minutes; thereafter, basophils were
added for 30minutes at 378C. Subsequently, cells were stimulated
with buffer or anti-IgE. Inversely, to block CD300a receptor on
isolated basophils, cells were exposed to different concentrations
of the monoclonal anti-human CD300a-blocking antibody TX-
496 at 378C for 30 minutes before adding aPBMC followed by
anti-IgE activation. These experiments showed that blocking
CD300a resulted in dose-dependent reversal of the magnitude
of inhibition up to 77% (Fig 2, A and C; P 5 .05). Preincubation
with anti-CD300a alone did not result in any significant effect on
basophil activation markers (data not shown). This is not in
contrast with our previous study,5 in which a CD300a
receptor-activating antibody (clone MEM-260) was used,
resulting in an inhibition of CD63 upregulation. Similarly,
preincubating the cells with recombinant human Annexin V
reversed the magnitude of aPBMC-induced inhibition up to
82% (Fig 2, B and D; P 5 .04).
Taken together, these results led us to conclude that
the interaction between PS and CD300a inhibits IgE/FcεRI-
dependent anaphylactic basophil degranulation. Nevertheless,
the biological or clinical relevance of basophilic response/
inhibition in IgE-mediated hypersensitivity needs to be
elucidated.
The externalization of PS in the absence of apoptosis as a
consequence of granular membrane fusion with the cell
membrane involving inversion of membrane leaflet polarity8
and upregulation of the inhibitory receptor CD300a during
basophilic degranulation5 on a single cell level may contribute
to self-terminating mechanisms through cis recognition.
Whether the finding of increased apoptosis of monocytes on
day 3 of venom immunotherapy9 suggests the involvement of
PS-CD300a interaction on the early suppression of basophils
and mast cells is a hypothesis that deserves investigation.
Finally, the modulation of basophilic phagocytic activity
through CD300a-PS interaction seems difficult to postulate
because these cells express low phagocytic activity.
In conclusion, we have for the first time demonstrated that
the apoptosis-related signal PS suppresses human basophil
anaphylactic degranulation via the inhibitory receptor CD300a
(IRp60). These data provide interesting input to study the role of
phospholipids recognition in modulation of basophilic responses
and endorse the role of CD300a as a pharmacologic target for the
treatment of allergic disease.
We thank Mrs Christel Mertens for her excellent technical support.1
FIG 1. Effect of apoptotic cells on IgE-mediated basophil activation in patients and controls and the specific
role of PS. A, Representative of 10 experiments. Apoptotic (a) K562 cells induce selective inhibition of CD63.
B, Inhibition of CD63 upregulation after anti-IgE stimulation in patients allergic to birch pollen (closed
circles) and controls (open circles) (**P < .05 for aK562 concentrations 20 3 107/mL and 10 3 107/mL).
The inhibitory effect is more pronounced in controls (##P < .05 controls vs patients). Results are expressed
as median (range). C, Inhibition of Bet v 1–induced CD63 upregulation (**P < .05 for aK562 concentrations
20 3 107/mL and 10 3 107/mL). Results are expressed as median (range). D, Only fluorescent PS- but not
PC-coated liposomes or noncoated liposomes stain basophilic membranes. E, Results of 2 independent
experiments with different concentration of PS- and PC-coated liposomes (closed and open squares and
closed and open circles, respectively). Only PS-coated liposomes downregulate CD63 appearance on
isolated basophils stimulated with anti-IgE. PC, Phosphorylcholine; PS, phosphatidylserine.
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FIG 2. CD300a-PS interaction: attenuation of the inhibitory signals delivered by apoptotic cells. A and C,
CD300a-blocking assays. A representative experiment with anti-IgE–stimulated basophils without aPBMC
and in the presence of aPBMC with or without blocking with the anti-CD300a TX-49 clone (10 mg/mL) (Fig
2, A). Individual results from 3 different experiments (Fig 2, C). CD300a blocking attenuates the magnitude
of inhibitory signals delivered by aPBMC in a dose-dependent manner (Fig 2, C; P 5 .05). B and D, Results
from human recombinant Annexin V–blocking assays. A representative experiment with anti-IgE–
stimulated basophils in the absence of aPBMC, in the presence of aPBMC, and in the presence of Annexin
V–blocked aPBMC (500 mg/mL) (Fig 2, B). Individual results from 3 different experiments are displayed
(Fig 2, D). Similarly to the CD300a-blocking experiments, Annexin V blocking attenuates the magnitude
of inhibitory signals delivered by aPBMC in a dose-dependent manner (P 5 .04).
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METHODS
Patients and ethics
Blood samples were drawn from 5 patients allergic to birch pollen
(2 men, median age, 36 year; range, 26–48 years) and 10 healthy volunteers
(3 men, median age, 40 year; range, 21-61 years).
The selection of patients was based on the history of spring-related
rhinoconjunctivitis and documented by standardized skin tests and
quantification of specific IgE.E1 Experiments were performed outside the
birch pollen season.
Approval for this study was obtained from the local ethical committee
(B300201318240). Patients and healthy control individuals provided an
informed consent.
Basophils
In the first experimental model, peripheral basophils in endotoxin-free
heparinized whole blood were studied. Subsequently, purified basophils were
obtained via a previously described immunomagnetic bead separation
protocol (EasySep Human Basophil Enrichment Kit; StemCell Technologies,
Vancouver, British Columbia, Canada).7
Experimental design
In the first set of experiments, we aimed at investigating the effect of
apoptotic cells on human peripheral blood basophils. Because of competition
with other peripheral blood cells, and as observed in preliminary tests, a
relatively high number of apoptotic cells was needed to alter basophil
responses. Therefore, in the whole blood experiment, we applied the
tumoral cell-line K562. On quantitative footing, when related to RBC,
the ratio K562/RBC is approximately 1/25 and 1/50 for the concentrations
20 3 107/mL and 10 3 107/mL, respectively.
To exclude whether the findings in these whole blood experiments could
result from alternative humoral factors or engagement by other peripheral
blood cells, we continued our investigations with isolated basophils. This
enabled us to reduce the apoptotic load while applying autologous apoptotic
PBMCs and to use liposomes as a source of PS.
Because of the artificial nature of liposomes, we chose apoptotic
autologous PBMCs as a potential natural source of PS to explore whether
inhibitory signals could be reverted by PS-binding molecules (such as
Annexin V) and a CD300a-blocking antibody (TX49).
Induction and quantification of apoptosis
To induce apoptosis in K562 cells, cells were treated in FCS-free RPMI
(Invitrogen, Paisely, United Kingdom)with 10mmol/L H2O2 for 15minutes at
378C. Subsequently, cells were spun and resuspended in RPMI with 2% FCS
and left in the CO2 incubator at 378C for 24 hours. Finally, cells were washed
and suspended in Tyrode’s buffer (Sigma-Aldrich, Seelze, Germany) and used
immediately.
Apoptosis was induced in Histopaque (Sigma)-isolated PBMCs with
10 mmol/L H2O2 for 2 hours. Cells were then washed and immediately
used in Tyrode’s buffer. Apoptosis was quantified with fluorescein
isothiocyanate–conjugated Annexin V and propidium iodide (BD Biosci-
ences, Erembodegem, Belgium). Experiments were performed only if more
than 90% of K562 cells or PBMCs were Annexin V positive.
Preparation of liposomes
Phosphatidylcholine and PS unilamellar liposomes were formed by a
method adopted by de la Maza.E2
Initially 1,2-dioleoyl, L-a-Phosphatidylcholine (DOPC; Sigma-Aldrich)
and 1,2-diacyl-sn-glycero-3-phospho-L-serine (PS; Sigma-Aldrich) were
dissolved in a 2:1 % v/v chloroform: methanol solution. DOPC and PS were
mixed in a round-bottom flask to achieve a 70:30 % molar ratio. DOPC
liposomes alone were formed by the addition of DOPC alone to the
round-bottom flask (100 % mol). Total lipid added was 5 mg in all cases.
The organic solvent was then evaporated under a stream of nitrogen gas
to achieve a lipid film. Residual solvent was removed by drying the
round-bottom flask for 2 hours at 508C.
The lipid film was then rehydrated using 3 mL HBSS with 25 mmol/L
HEPES (Invitrogen) at 508C to achieve a final lipid concentration of
10 mmol/L. Rehydration took place over 2 hours in a 458C water bath.
Following this, the liposome suspension was subject to 21 cycles of extrusion
through a 100-nm filter to achieve a 100 nm unilamellar liposome suspension.
Extrusion took place at 458C. The formed liposome suspension was then
sterilized using a 200-nm filter before application to the cells.
Where appropriate, 5(6)-carboxyfluorescein (CF; Sigma-Aldrich) was
encapsulated into the DOPC/PS and DOPC-only liposomes. This occurred
at the rehydration stage, whereby CF was dissolved in HBSS with 25 mmol/L
HEPES to achieve a 1.32 mmol/L solution. Unencapsulated dye was removed
by centrifugation of the liposome suspension at 13,000 rpm for 30 minutes.
The pellet was then resuspended in 3 mL HBSS with 25 mmol/L HEPES.
CF-loaded liposomes were also extruded through a 100-nm filter at 458C to
achieve a unilamellar liposome population and sterilized before use.
Interaction of liposomes with basophils
Fluorescein-stained liposomes, noncoated or coated with PS or
phosphorylcholine, were added to isolated basophils of 2 healthy donors at
48C for 20 minutes and immediately assessed by flow cytometry to evaluate
the specific binding of PS.
Next, the functional effect of noncoated and PS- and phosphorylcholine-
coated nonstained liposomes was assessed by preincubating different
concentrations of liposomes (starting from a ratio basophils/liposomes of
1/20) with isolated basophils at 378C for 30 minutes before anti-IgE
stimulation (see below).
Stimulation conditions
Whole blood or isolated basophils were challenged (378C, 20minutes) with
100 mL of anti-IgE (10 mg/mL; clone G7-18, BD Biosciences) and activation
buffer. In allergic patients, additional stimulation experiments involved
recombinant Betula verrucosa 1 (rBet v 1; 1 mg/mL; Stallergenes, Antony,
France), a concentration optimized elsewhere.E1 Cells were stimulated for
20 minutes at 378C.
Immunophenotyping and flow cytometric analysis
Activation was stopped by cooling the cells on ice. Thereafter, basophils
were stained with 20mL anti-human IgE (clone GE-1, SigmaAldrich) labeled
with Alexa Fluor 405 (Molecular Probes, Invitrogen), 10 mL anti-human
CD63-fluorescein isothiocyanate (clone H5C6, BD Biosciences), and 10 mL
anti-human CD203c-APC (clone NP4D6 Biolegend, San Diego, Calif) for 20
minutes on ice. Red blood cells were lysed and white blood cells were fixed
(FACS, BD) for 20 minutes at room temperature.
Flow cytometric quantification of upregulation of CD63 and CD203c was
performed with a FACSCanto II flow cytometer (BD Immunocytometry
Systems, San Jose, Calif) using a selective region on basophils. Basophils
were selected as low SSC-A, IgE1/CD203c1 cells, excluding aggregates. In
preliminary experiments, dead cells, stained by near-IR live/dead dye, were
visualized in the gate of double-negative basophils (CD203cdimCD632).
To exclude the possible interference of apoptotic cells in the basophil region
during analysis, CD63 upregulation measurement was restricted to the
CD203c1bright basophils.
At least 1000 CD203c1bright basophils were acquired (interassay vari-
ability,63%). Results (in %) of CD63 upregulation are normalized according
to the formula: normalized % CD631 basophils 5 (%CD631experiment/%
CD631 with anti-IgE stimulation) 3 100.
Statistical analysis
All the data were expressed as median (range). Nonparametric
Mann-Whitney and Wilcoxon tests were applied where appropriate. P values
of less than .05 were considered as significant.
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FIG E1. A representative example of liposomes and basophil interaction experiments. The plots display
spontaneous expression of CD203c and CD63 on unstimulated (A-C) and anti-IgE–stimulated (D-F) isolated
basophils. Noncoated (Fig E1, A), PC-coated (Fig E1, B), and PS-coated (Fig E1, C) liposomes do not alter the
spontaneous expression of CD63 and CD203c. In contrast to noncoated (Fig E1, D) and PC-coated (Fig E1, E)
liposomes, PS-coated liposomes exert an inhibitory effect on anti-IgE–dependent CD63 upregulation
(Fig E1, F). PC, Phosphorylcholine; PS, phosphatidylserine.
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